Konstanze Döhner

Q: What Schools Are Affiliated With Konstanze Döhner

Konstanze Döhner is affiliated with the following schools: University of Ulm, Hannover Medical School, University of Tübingen, Technical University of Munich, University of Münster

Konstanze Döhner's AcademicInfluence.com Rankings

Konstanze Döhner

Medical

#2537

World Rank

#2965

Historical Rank

Hematology

#34

World Rank

#40

Historical Rank

Oncology

#158

World Rank

#164

Historical Rank

medical Degrees

Konstanze Döhner

Philosophy

#7324

World Rank

#10518

Historical Rank

Logic

#4385

World Rank

#5668

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Konstanze Döhner Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Konstanze Döhner's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. (2005) (2933)
Genomic aberrations and survival in chronic lymphocytic leukemia. (2000) (2740)
Genomic Classification and Prognosis in Acute Myeloid Leukemia. (2016) (2608)
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. (2008) (1608)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation (2017) (1382)
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. (2013) (1143)
Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. (2004) (985)
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. (2002) (872)
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. (2005) (860)
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. (2010) (766)
Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations (2012) (755)
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. (2018) (689)
Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells (2009) (546)
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. (2012) (539)
A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia (2014) (518)
CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. (2004) (475)
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. (2012) (472)
RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. (2011) (406)
Effect of mutation order on myeloproliferative neoplasms. (2015) (397)
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. (2011) (389)
Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. (2011) (364)
Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. (2011) (356)
Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. (2014) (343)
Genomics of Acute Myeloid Leukemia Diagnosis and Pathways. (2017) (330)
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. (2004) (327)
Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. (2002) (324)
Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. (2006) (298)
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia (2016) (279)
Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis (1999) (268)
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. (2017) (265)
Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. (2009) (256)
High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. (2010) (243)
High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. (2006) (241)
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. (2006) (236)
An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. (2012) (215)
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. (2010) (210)
Human Chromosome 7: DNA Sequence and Biology (2003) (208)
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. (2014) (206)
Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. (2010) (206)
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. (2019) (205)
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. (2007) (203)
Precision oncology for acute myeloid leukemia using a knowledge bank approach (2017) (200)
Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B (2009) (200)
A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy (2012) (198)
RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features (2016) (193)
Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. (2009) (188)
The genomic landscape of core-binding factor acute myeloid leukemias (2016) (187)
TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. (2012) (186)
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. (2018) (184)
Molecular characterization of acute myeloid leukemia (2008) (183)
Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. (2012) (178)
Cell of origin determines clinically relevant subtypes of MLL-rearranged AML (2013) (173)
DNMT3A mutations in myeloproliferative neoplasms (2011) (172)
Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease (2008) (169)
Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. (2006) (167)
Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). (2013) (164)
Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. (2013) (162)
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia (2004) (160)
Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma (1998) (160)
Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. (2010) (160)
Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. (2014) (159)
Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). (2013) (156)
Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. (2012) (151)
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms (2015) (151)
Inactivating I kappa B epsilon mutations in Hodgkin/Reed–Sternberg cells (2003) (151)
The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis. (2007) (147)
The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. (2013) (142)
Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. (2013) (141)
Disease evolution and outcomes in familial AML with germline CEBPA mutations. (2015) (137)
Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup. (2012) (133)
Risk-adapted postremission therapy in acute myeloid leukemia: results of the german multicenter AML HD93 treatment trial (2003) (130)
Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. (2010) (128)
Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing. (2012) (127)
Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia (2010) (127)
Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. (2005) (126)
Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis (2010) (126)
Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. (2002) (125)
Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. (2010) (123)
PBX3 is an important cofactor of HOXA9 in leukemogenesis. (2013) (119)
Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. (2012) (118)
2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document. (2021) (112)
Inactivating CUX1 mutations promote tumorigenesis (2013) (111)
Quantification of CBFβ/MYH11 fusion transcript by Real Time RT-PCR in patients with INV(16) acute myeloid leukemia (2001) (110)
Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells. (2011) (110)
TET genes: new players in DNA demethylation and important determinants for stemness. (2011) (108)
Molecular cytogenetic characterization of a critical region in bands 7q35-q36 commonly deleted in malignant myeloid disorders. (1998) (107)
Incidence and clinical significance of 6q deletions in B cell chronic lymphocytic leukemia (1999) (106)
An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. (2008) (105)
Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms (2013) (104)
Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. (2008) (102)
JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. (2012) (102)
Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors. (2011) (102)
Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia (2020) (102)
Impaired function of primitive hematopoietic cells in mice lacking the Mixed-Lineage-Leukemia homolog MLL5. (2009) (99)
Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO) (2017) (98)
Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation (2019) (95)
Abelson Tyrosine Kinase Controls Phagosomal Acidification Required for Killing of Mycobacterium tuberculosis in Human Macrophages (2011) (90)
Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes (2014) (90)
A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations (2015) (88)
Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks. (2011) (86)
Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. (2013) (85)
Cdx4 dysregulates Hox gene expression and generates acute myeloid leukemia alone and in cooperation with Meis1a in a murine model (2006) (85)
NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. (2012) (84)
Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia. (2019) (84)
Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. (2009) (81)
Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. (2014) (76)
Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure (2017) (76)
High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia. (2012) (74)
Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways. (2015) (74)
ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group (2015) (73)
High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. (2010) (71)
Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial (2018) (70)
Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia (2012) (66)
Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. (2014) (66)
Gene expression profiling in AML with normal karyotype can predict mutations for molecular markers and allows novel insights into perturbed biological pathways (2010) (65)
MPN patients harbor recurrent truncating mutations in transcription factor NF-E2 (2013) (64)
Impact of new prognostic markers in treatment decisions in acute myeloid leukemia (2009) (63)
Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia. (2001) (63)
Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. (2006) (62)
Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia (2017) (62)
Measurable Residual Disease Monitoring in Acute Myeloid Leukemia with t(8;21)(q22;q22.1): Results of the AML Study Group. (2019) (61)
Caspase-8L expression protects CD34+ hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis (2005) (60)
Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation? (2013) (60)
Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut). (2013) (59)
Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study (2018) (59)
SEURAT: Visual analytics for the integrated analysis of microarray data (2010) (57)
Clinical implications of subclonal TP53 mutations in acute myeloid leukemia (2018) (55)
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. (2021) (55)
High-resolution single-nucleotide polymorphism array-profiling in myeloproliferative neoplasms identifies novel genomic aberrations (2010) (54)
All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study (2016) (54)
Molecular profiling reveals myeloid leukemia cell lines to be faithful model systems characterized by distinct genomic aberrations (2006) (52)
Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia. (2011) (51)
Molecular cytogenetic analysis of B-cell chronic lymphocytic leukemia (1998) (51)
High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia (2005) (51)
Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. (2016) (51)
CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARγ signaling. (2013) (50)
KIT mutations confer a distinct gene expression signature in core binding factor leukaemia (2010) (50)
Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance (2013) (50)
Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation. (2018) (50)
Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules. (2006) (48)
Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia (2013) (48)
DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia (2018) (46)
Quantitative analyses of DAPK1 methylation in AML and MDS (2012) (45)
Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment Trial (2006) (45)
Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid Leukemia. (2018) (44)
An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations (2017) (44)
The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML (2013) (44)
Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia (2017) (44)
Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis (2017) (43)
Chromothripsis is linked to TP53 alteration, cell cycle impairment, and dismal outcome in acute myeloid leukemia with complex karyotype (2018) (43)
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group (2016) (43)
Mutation analysis of the transcription factor PU.1 in younger adults (16 to 60 years) with acute myeloid leukemia: a study of the AML Study Group Ulm (AMLSG ULM). (2003) (41)
The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia. (2005) (40)
Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia. (2017) (40)
Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia (2011) (40)
All-Trans Retinoic Acid Improves Outcome in Younger Adult Patients with Nucleophosmin-1 Mutated Acute Myeloid Leukemia – Results of the AMLSG 07-04 Randomized Treatment Trial (2011) (39)
Vaccination with autologous non‐irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia (2007) (38)
Midostaurin in Combination with Intensive Induction and As Single Agent Maintenance Therapy after Consolidation Therapy with Allogeneic Hematopoietic Stem Cell Transplantation or High-Dose Cytarabine (NCT01477606) (2015) (38)
Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss‐of‐function mutations (2005) (35)
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia (2016) (35)
JAK2V617F mutations as cooperative genetic lesions in t(8;21)-positive acute myeloid leukemia. (2006) (35)
High BRE expression predicts favorable outcome in adult acute myeloid leukemia, in particular among MLL-AF9-positive patients. (2011) (35)
Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo (2016) (34)
Functional Classification of TP53 Mutations in Acute Myeloid Leukemia (2019) (34)
getITD for FLT3-ITD-based MRD monitoring in AML (2019) (34)
Impact of gemtuzumab ozogamicin on MRD and relapse risk in NPM1 mutated AML patients: results from the AMLSG 09-09 Trial. (2020) (34)
Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial. (2019) (34)
Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia (2012) (34)
Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase (2017) (34)
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial (2021) (34)
The clathrin-binding domain of CALM and the OM-LZ domain of AF10 are sufficient to induce acute myeloid leukemia in mice (2011) (33)
PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation—A Possible Target for ATRA Response in AML without t(15;17) (2013) (33)
Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group (2016) (32)
Epo-induced erythroid maturation is dependent on Plcγ1 signaling (2013) (32)
Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. (2021) (31)
Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroups (2011) (31)
Cancer-specific changes in DNA methylation reveal aberrant silencing and activation of enhancers in leukemia. (2017) (30)
Intermediate-risk acute myeloid leukemia therapy: current and future. (2014) (30)
Development of a real‐time RT‐PCR assay for the quantification of the most frequent MLL/AF9 fusion types resulting from translocation t(9;11)(p22;q23) in acute myeloid leukemia (2003) (29)
ASXL 1 mutations in younger adult patients with acute myeloid leukemia : a study by the German-Austrian Acute Myeloid Leukemia Study Group (2015) (29)
Germline variants drive myelodysplastic syndrome in young adults (2021) (29)
Allogeneic stem cell transplant to eliminate germline mutations in the gene for CCAAT-enhancer-binding protein α from hematopoietic cells in a family with AML (2011) (28)
GPR56 contributes to the development of acute myeloid leukemia in mice (2016) (28)
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results (2021) (28)
Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia (2014) (28)
Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence (2013) (28)
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. (2020) (27)
RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features (2016) (26)
Risk-Adapted Therapy in Younger Adults with Acute Myeloid Leukemia: Results of the AMLHD98A Trial of the AMLSG. (2006) (26)
Tracing the development of acute myeloid leukemia in CBL syndrome. (2014) (26)
Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia (2012) (25)
Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication. (2020) (24)
Mitochondrial BAX Determines the Predisposition to Apoptosis in Human AML (2017) (24)
Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial. (2020) (23)
Haploinsufficiency of ETV6 and CDKN1B in patients with acute myeloid leukemia and complex karyotype (2014) (23)
Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3-ITD: Interim-Analyses of the AMLSG 16-10 Trial (2016) (23)
Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML (2019) (22)
Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q (2015) (22)
MiR-139-5p is a potent tumor suppressor in adult acute myeloid leukemia (2016) (22)
PHASE III RANDOMIZED TRIAL OF VOLASERTIB PLUS LOW-DOSE CYTARABINE (LDAC) VERSUS PLACEBO PLUS LDAC IN PATIENTS AGED >= 65 YEARS WITH PREVIOUSLY UNTREATED AML, INELIGIBLE FOR INTENSIVE THERAPY (2016) (22)
A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1) (2008) (22)
Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo (2020) (22)
TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition (2020) (21)
The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations (2017) (21)
Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms (2010) (21)
MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML. (2016) (21)
Unified classification and risk-stratification in Acute Myeloid Leukemia (2022) (20)
Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy (2017) (20)
Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks (2016) (19)
Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia‐associated antigens (2015) (19)
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia (2021) (19)
Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy (2016) (18)
Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/mL) (2019) (18)
Diagnostic value of fluorescence in situ hybridization for the detection of genomic aberrations in older patients with acute myeloid leukemia. (2005) (18)
Leukemic stem cells of acute myeloid leukemia patients carrying NPM1 mutation are candidates for targeted immunotherapy (2014) (18)
Chronic lymphocytic leukaemia and acute myeloid leukaemia are not associated with AKT1 pleckstrin homology domain (E17K) mutations (2008) (18)
Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis (2017) (17)
KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis (2019) (17)
Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group (2017) (17)
STAT1 activation in association with JAK2 exon 12 mutations (2016) (17)
Efficacy and Safety Of Fedratinib (SAR302503/TG101348) In Patients With Intermediate- Or High-Risk Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Or Post-Essential Thrombocythemia (ET) MF Previously Treated With Ruxolitinib: Interim Results From a Phase II Study (JAKARTA-2) (2013) (17)
Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation (2017) (17)
TET2 Mutations In Acute Myeloid Leukemia (AML): Results on 783 Patients Treated within the AML HD98A Study of the AML Study Group (AMLSG) (2010) (16)
Attenuated Expression of Apoptosis Stimulating Protein of p53-2 (ASPP2) in Human Acute Leukemia Is Associated with Therapy Failure (2013) (16)
Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All-Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients (2016) (16)
Gene Mutations as Predicitive Markers for Postremission Therapy in Younger Adults with Normal Karyotype AML. (2006) (16)
Minimal Residual Disease Monitoring in Acute Myeloid Leukemia (AML) with Translocation t(8;21)(q22;q22): Results of the AML Study Group (AMLSG) (2016) (15)
Differences in expression and function of LEF1 isoforms in normal versus leukemic hematopoiesis (2019) (15)
The leukemogenicity of Hoxa9 depends on alternative splicing (2014) (15)
Impact of Allogeneic Transplantation From Matched Related and Unrelated Donors on Clinical Outcome In Younger Adult AML Patients with FLT3 Internal Tandem Duplications (2010) (15)
Stable and reproducible engraftment of primary adult and pediatric acute myeloid leukemia in NSG mice (2011) (15)
Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers (2016) (14)
Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia (2020) (14)
Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. (2017) (14)
Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1) (2019) (14)
Sunitinib and Intensive Chemotherapy in Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations: Results of the AMLSG 10-07 Study (ClinicalTrials.gov No. NCT00783653) (2012) (14)
MicroRNA-708 is a novel regulator of the Hoxa9 program in myeloid cells (2019) (13)
Updated Results from the German Mpnsg-0212 Combination Trial: Ruxolitinib Plus Pomalidomide in Myelofibrosis with Anemia (2019) (13)
A Phase-Ib/II Study of Ruxolitinib Plus Pomalidomide in Myelofibrosis (2015) (13)
Prognostic Impact of NPM1/FLT3-ITD genotypes from Randomized Patients with Acute Myeloid Leukemia (AML) Treated within the International Ratify Study (2017) (13)
MicroRNA-155 is upregulated in MLL-rearranged AML but its absence does not affect leukemia development. (2016) (13)
Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations (2017) (12)
Improved Outcome with ATRA-Arsenic Trioxide Compared to ATRA-Chemotherapy in Non-High Risk Acute Promyelocytic Leukemia – Updated Results of the Italian-German APL0406 Trial on the Extended Final Series (2014) (12)
Introduction: Acute Myeloid Leukemia (2008) (12)
Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia (2015) (12)
Mutation analysis of the origin recognition complex subunit 5 (ORC5L) gene in adult patients with myeloid leukemias exhibiting deletions of chromosome band 7q22 (2001) (12)
VENTX induces expansion of primitive erythroid cells and contributes to the development of acute myeloid leukemia in mice (2016) (11)
Genome-wide genotyping of acute myeloid leukemia with translocation t(9;11)(p22;q23) reveals novel recurrent genomic alterations (2014) (11)
CDK4/6 Inhibitor Palbociclib for Treatment of KMT2A-Rearranged Acute Myeloid Leukemia: Interim Analysis of the AMLSG 23-14 Trial (2016) (11)
Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study (2020) (10)
Reduced‐intensity conditioning followed by T‐cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse (2007) (10)
Deregulated expression of circular RNAs in acute myeloid leukemia. (2018) (10)
PBX 3 is an important cofactor of HOXA 9 in leukemogenesis * (2013) (10)
A Phase I/II Study Combining Sunitinib with Standard Ara-C/Daunorubicin Chemotherapy In Patients 60 Years or Older with FLT3 Mutated AML (2010) (9)
The Genotype NPM1mut/FLT3-ITDneg Is a Highly Significant Predictive Factor for Response to Therapy with All-Trans Retinoic Acid in Acute Myeloid Leukemia - Results from AMLSG Trial AML HD98B. (2007) (9)
CEBPA Germline Mutation Screening in Cytogenetically Normal Acute Myeloid Leukemia with Somatically Acquired CEBPA Mutations. (2007) (9)
Deletion of the multidrug resistance-associated protein (MRP1) gene in acute myeloid leukemia with inversion of chromosome 16 has no prognostic impact (2000) (9)
S879 RESULTS OF ASTRAL-1 STUDY, A PHASE 3 RANDOMIZED TRIAL OF GUADECITABINE (G) VS TREATMENT CHOICE (TC) IN TREATMENT NAÏVE ACUTE MYELOID LEUKEMIA (TN-AML) NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY (IC) (2019) (9)
Insomnia, Quality Of Life and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG) (2013) (8)
Clinical Impact of WT1 Mutations in the Context of Other Molecular Markers in Cytogenetically Normal Acute Myeloid Leukemia (AML): A Study of the German-Austrian AML Study Group (AMLSG). (2007) (8)
PLCG1 is required for AML1-ETO leukemia stem cell self-renewal. (2021) (8)
Micro-ribonucleic acid-155 is a direct target of Meis1, but not a driver in acute myeloid leukemia (2017) (8)
The High Prevalence of FLT3-ITD Mutations Is Associated with the Poor Outcome in Adult Patients with t(6;9)(p23;q34) Positive AML - Results of an International Metaanalysis. (2007) (8)
Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN (2020) (8)
Molecular characterization of AML with ins(21;8)(q22;q22q22) reveals similarity to t(8;21) AML (2011) (8)
Clonal Evolution of FLT3 -ITD Positive AML in Patients Treated with Midostaurin in Combination with Chemotherapy within the Ratify (CALGB 10603) and AMLSG 16-10 Trials (2017) (8)
Acute myeloid leukemia. Introduction. (2008) (7)
Netboost: Boosting-Supported Network Analysis Improves High-Dimensional Omics Prediction in Acute Myeloid Leukemia and Huntington’s Disease (2019) (7)
MicroRNA expression-based outcome prediction in acute myeloid leukemia: novel insights through cross-platform integrative analyses (2016) (7)
Postremission Therapy with an Allogeneic Transplantation from an HLA-Matched Family Donor Seems To Overcome the Negative Prognostic Impact of FLT3 -ITD in Younger Patients with Acute Myeloid Leukemia Exhibiting a Normal Karyotype. (2005) (7)
Protein phosphatase 4 regulatory subunit 2 (PPP4R2) is recurrently deleted in acute myeloid leukemia and required for efficient DNA double strand break repair (2017) (7)
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications (2022) (7)
UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment (2022) (7)
Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603) (2018) (6)
TP53 mutated AML subclones exhibit engraftment in a humanized bone marrow ossicle mouse model (2020) (6)
Sexuality Challenges, Intimacy, and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG) (2013) (6)
EU-Wide Access to High-quality, Affordable Precision Diagnostics: An EHA Position Paper (2020) (6)
S1608 RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA: RESULTS FROM THE MPNSG-0212 COMBINATION TRIAL (NCT01644110) (2019) (6)
Aberrant Expression of the Homeobox Gene CDX2 in Acute Myeloid Leukemia. (2006) (6)
Analysis of NPM1 splice variants reveals differential expression patterns of prognostic value in acute myeloid leukemia (2017) (6)
Decitabine Response Associated Gene Expression Patterns In Acute Myeloid Leukemia (AML) (2013) (6)
Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1-mutated acute myeloid leukemia receiving gemtuzumab ozogamicin (2021) (6)
Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry (2021) (6)
Defining disease modification in myelofibrosis in the era of targeted therapy (2022) (6)
Mutations in the Fms-Related Tyrosine Kinase 3 (FLT3) Gene Independently Predict Poor Outcome in Acute Myeloid Leukemia (AML) with t(8;21): A Study of the German-Austrian AML Study Group (AMLSG). (2009) (5)
Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial (2021) (5)
Type and Number of Secondary Molecular Lesions Improve Outcome Prediction in Acute Myeloid Leukemia (AML) with inv(16) or t(16;16): A Study of the German-Austrian AML Study Group (AMLSG). (2009) (5)
Monitoring of Minimal Residual Disease (MRD) of DNMT3A Mutations (DNMT3Amut) in Acute Myeloid Leukemia (AML): A Study of the AML Study Group (AMLSG) (2015) (5)
AML bearing the translocation t(11;17)(q23;q21): involvement of MLL and a region close to RARA, with no differentiation response to retinoic acid (2005) (5)
Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes (2017) (5)
Detection of RAS, KIT and FLT3 Gene Mutations in t(8;21)-Positive Acute Myeloid Leukemia (AML): Evaluation of the Clinical Relevance. (2006) (5)
Ruxolitinib Plus Pomalidomide in Myelofibrosis: Updated Results from the Mpnsg-0212 Trial (NCT01644110) (2016) (5)
Chemotherapy and All-Trans Retinoic Acid in Patients >60 Years with Acute Myeloid Leukemia: First Results of the Multicenter Treatment Trial AML HD98-B (2001) (5)
The microRNA miR-196b acts as a tumor suppressor in Cdx2-driven acute myeloid leukemia (2020) (5)
Dissecting Genetic and Phenotypic Heterogeneity to Map Molecular Phylogenies and Deliver Personalized Outcome and Treatment Predictions in AML (2015) (5)
PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary or Secondary Myelofibrosis and Severe Thrombocytopenia (2021) (5)
Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine (2019) (5)
Use of Machine Learning in 2074 Cases of Acute Myeloid Leukemia for Genetic Risk Profiling (2019) (4)
Azacitidine-Containing Induction Regimens Followed by Azacitidine Maintenance Therapy in High Risk Acute Myeloid Leukemia: First Results of the Randomized Phase-II AMLSG 12-09 Study (ClinicalTrials.gov No. NCT01180322) (2012) (4)
A review of hydroxyurea-related cutaneous adverse events (2021) (4)
Pomalidomide In MPN–associated Myelofibrosis With Cytopenia: Results Of The Mpnsg 01-09 Study (2013) (4)
The ParaHox gene Cdx4 induces acute erythroid leukemia in mice. (2019) (4)
Valproic Acid as Adjunct to Induction Therapy in Patients with Acute Myeloid Leukemia: First Results of Two Randomized Studies of the AMLSG. (2005) (4)
Long-Term Interferon-α Treatment in Essential Thrombocythemia (2015) (4)
Detection of mutant NPM1 mRNA in acute myeloid leukemia using custom gene expression arrays. (2013) (4)
FLT3mutation Assay Laboratory Cross Validation: Results from the CALGB 10603/Ratify Trial in Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) (2018) (4)
Role of Etoposide in Combination with All- Trans Retinoic Acid in the Treatment of Elderly Patients with Acute Myeloid Leukemia and NPM1 Mutation (2008) (4)
A Multicenter Phase-Ib/II Study of Ruxolitinib/Pomalidomide Combination Therapy in Patients with Primary and Secondary Myelofibrosis: Safety Data from the Mpnsg-0212 Trial (NCT01644110) (2014) (4)
Genome-Wide DNA Methylation Analysis Shows Enrichment of Differential Methylation in “Open Seas” and Enhancers and Reveals Hypomethylation in DNMT3A Mutated Cytogenetically Normal AML (CN-AML) (2012) (4)
Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome (2018) (4)
Comment on ‘Integrative genomic profiling of human prostate cancer’ (2010) (4)
BH3 Profiling Predicts On-Target Cell Death Due To Selective Inhibition Of BCL-2 By ABT-199 In Acute Myelogenous Leukemia (2013) (3)
Monitoring of FLT3 Phosphorylation and FLT3 Ligand Levels in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) Treated with Midostaurin within the AMLSG 16-10 Trial of the German-Austrian Study Group (2018) (3)
ASXL1 Mutations Predict for Resistance to Chemotherapy and Inferior Outcome in Younger Adult Patients with Acute Myeloid Leukemia (AML): A Study of the German-Austrian AMLSG (2011) (3)
Identification of Clinically Relevant Predictive MRD Checkpoints in AML Patients with NPM1 Mutations: A Study of the AML Study Group (AMLSG). (2009) (3)
Higher Dose of CPX-351 Is Associated with Prolonged Hematologic Recovery: Results from an Interim Safety Analysis of the Randomized, Phase III AMLSG 30-18 Trial (2020) (3)
Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy (2018) (3)
The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia. (2017) (3)
Gender Differences and MPN Symptom Burden : An Analysis by the MPN Quality of Life International Study Group (MPN-QOL ISG) (2014) (3)
Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls (2020) (3)
Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia (2015) (3)
Analysis of Loss of Heterozygosity in Adult Patients with De Novo Acute Myeloid Leukemia and Normal Karyotype. (2006) (3)
Mutations of EZH2 In Myeloproliferative Neoplasms with Myelofibrosis: Correlation with Molecular and Clinical Data (2010) (3)
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial (2022) (3)
Monitoring of Minimal Residual Disease in NPM1 Mutated Acute Myeloid Leukemia (AML): Results of the AML Study Group (AMLSG) (2008) (3)
Acute Myeloid Leukemia (AML) with 9q Aberrations Occuring within a Non-Complex Karyotype Is Highly Associated with CEBPA and NPM1 Mutations - A Joint Analysis of the German-Austrian AML Study Group (AMLSG) and Cancer and Leukemia Group B (CALGB). (2007) (3)
Molecular Characterization of Distinct Hot Spot Regions on Chromosome 7q in Myeloid Leukemias. (2006) (3)
Personally Tailored Risk Prediction of AML Based on Comprehensive Genomic and Clinical Data (2015) (3)
Post Transplantation Measurable Residual Disease (MRD) Monitoring Using Next-Generation Sequencing Is Highly Predictive for Relapseafter Allogeneic Stem Cell Transplantation (2019) (3)
Pharmacodynamic Monitoring of the Efficacy of a Targeted Therapy with Midostaurin By Plasma Inhibitor Activity (PIA) Analysis in FLT3 -ITD Positive AML Patients within the AMLSG 16-10 Trial: A Study of the AML Study Group (AMLSG) (2015) (3)
Chronische myeloproliferative Neoplasien (2014) (3)
Symptom Severity and Clinical Variables of Polycythemia Vera Patients with Splenomegaly, Phlebotomy Requirements and/or Hydroxyurea Use : a Retrospective Evaluation of 1334 Patients (2014) (3)
Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias (2011) (3)
First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience (2021) (3)
Prognostic Impact of Mutant to Wild-Type Ratio and Insertion Site in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication (2012) (3)
The PARP Inhibitor Olaparib Antagonizes Leukemic Growth Induced By TET1 Overexpression in AML1-ETO Positive Acute Myeloid Leukemia (2016) (3)
DNMT3A mutations Predict for Inferior Outcome in NPM1-Wildtype and Molecular Unfavorable Cytogenetically-Normal Acute Myeloid Leukemia: A Study of the German-Austrian AMLSG (2011) (2)
Impact of Pegfilgrastim on Hematological Reconstitution and Incidence of Neutropenic Fever after Consolidation Therapy with High-Dose Cytarabine in Acute Myeloid Leukemia: Comparative Analysis between AMLSG 07-04 and the German AML Intergroup Trial. (2006) (2)
Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance (2022) (2)
Midostaurin Plus Intensive Chemotherapy for Younger and Older Patients with Acute Myeloid Leukemia and FLT3 Internal Tandem Duplications (2021) (2)
Chronic Myeloid Leukemia (CML) Cells Express Tumor Associated Antigens Eliciting Specific CD8+ T Cell Responses Despite of Deficient Expression of Costimulatory Molecules. (2005) (2)
Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17‐10 CIARA trial) (2018) (2)
Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs) (2015) (2)
Different Incidence and Implications of DNA Hypermethylation in De Novo AML Compared to High-Risk MDS and AML Following MDS. (2008) (2)
Rush hour in AML: news on NPM traffic (2006) (2)
Differential DNA Methylation Predicts Response To Combined Treatment Regimens With a DNA Methyltransferase Inhibitor In Acute Myeloid Leukemia (AML) (2013) (2)
Pomalidomide in Myelofibrosis with Cytopenia: First Results of the Mpnsg 01–09 Study (ClinicalTrials.gov Identifier: NCT00949364). (2012) (2)
Results of the “Evaluation of NGS in AML-Diagnostics (ELAN)” Study – an Inter-Laboratory Comparison Performed in 10 European Laboratories (2014) (2)
Correction: Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study (2020) (2)
Broad genomic workup including optical genome mapping uncovers a DDX3X: MLLT10 gene fusion in acute myeloid leukemia (2022) (2)
S1616 MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA (AML) WITH T(8;21)(Q22;Q22.1); RUNX1-RUNX1T1: RESULTS OF THE AML STUDY GROUP (AMLSG) (2019) (2)
Machine Learning of Genomic Factors in 1,961 Patients with Acute Myeloid Leukemia Identifies Patients with Very Good or Very Poor Prognosis Who Do Not Benefit from Allogeneic Hematopoietic Cell Transplant in First Remission (2021) (2)
Association of FLT3-internal tandem duplication length with overall survival in acute myeloid leukemia: a systematic review and meta-analysis (2022) (2)
Analysis of the ETS Family Member Genes ERG, ETS2, ETS1 and FLI1 in Acute Myeloid Leukemia (AML) Patients with Normal Cytogenetics: Expression Levels and Impact On Clinical Outcome. A Study of the AMLSG. (2009) (2)
Ruxolitinib Shows Efficacy in Patients with Newly-Diagnosed Polycythemia Vera: Futility Analysis of the Randomized Ruxo-BEAT Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (2019) (2)
Integration of Hi-C and Nanopore Sequencing for Structural Variant Analysis in AML with a Complex Karyotype: (Chromothripsis)² (2020) (2)
Associations between gender , disease features and symptom burden in the MPN population : An analysis by the MPN QOL International Working Group (2016) (2)
Gene Expression Profiling in AML with Normal Karyotype: A Multicenter Study Investigating Molecular Markers in 252 Cases (2008) (2)
Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN (2021) (2)
Knockdown Of The Piwi - Like Protein 4 (PIWIL4) Delays Leukemic Growth and Is Associated With Gross Changes In The Global Histone Methylation Marks In Human MLL - Rearranged AML (2013) (2)
Haploinsufficiency of ETV6 and CDKN1B in patients with acute myeloid leukemia and complex karyotype (2014) (2)
The miRNA-193 Family Is a Potent Tumor-Suppressor and a Biomarker for Poor Prognosis in Acute Myeloid Leukemia (2016) (2)
The EHA Research Roadmap: Malignant Myeloid Diseases (2021) (2)
Next-Generation Sequencing (NGS)-Based Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication (FLT3-ITD+ AML) Treated with Additional Midostaurin (2020) (2)
Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia (2022) (2)
Identification of Partial Tandem Duplications of the MLL Gene in Acute Myeloid Leukemia: Prospective Analysis within the Multicenter Treatment Trial AML HD98-A (2003) (2)
All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct to High-Dose Cytarabine-Based Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of AMLSG 05-04 Trial. (2007) (2)
Clinical Relevance of Minimal Residual Disease Monitoring in NPM1 Mutated AML: A Study of the AML Study Group (AMLSG) (2015) (2)
Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia (2022) (2)
PRIMARY MYELOFIBROSIS, POST-ET AND POST-PV MYELOFIBROSIS HAVE DISTINCT CLINICAL PROFILES AND SYMPTOMATIC BURDENS : AN ANALYSIS BY THE MPN QUALITY OF LIFE INTERNATIONAL STUDY GROUP (MPN-QOL ISG) (2015) (2)
Randomized Phase II Study of All-Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status (2021) (2)
Prognostic Implication of Insertion of FLT3 Internal Tandem Duplication in the BETA-1-Sheet of the Tyrosine Kinase Domain-1 (2008) (1)
AML1-ETO Collaborates with the TALE Homeobox Genes MEIS1 and MEIS2 in Inducing AML. (2012) (1)
Prognosis of Adult Patients ≤60 Years with AML and Aberrations of Chromosome 11q23: Pooled Data Analysis of the AML-SG and SHG-Dresden Study Groups. (2005) (1)
Interdependency Between TP53 Mutations, Cytogenetics, Genetic Instability and Prognosis in MDS and Secondary AML (2016) (1)
Clonal Evolution in NPM1 Mutated Acute Myeloid Leukemia (AML) (2015) (1)
Deregulated Apoptotic Pathways Point to Effectiveness of IAP Inhibitor Therapy in Acute Myeloid Leukemia. (2009) (1)
[Acute myeloid leukemia. Genetic diagnostics and molecular therapy]. (2013) (1)
Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603) (2018) (1)
Characterization of NPM1 -Mutated/ FLT3 ITD-Negative Acute Myeloid Leukemia with Normal Karyotype by Gene Expression Profiling. (2006) (1)
TET2 deficiency cooperates with CBFB‐MYH11 to induce acute myeloid leukaemia and represents an early leukaemogenic event (2022) (1)
P448: PROGNOSTIC IMPACT OF SOMATIC CEBPA BZIP DOMAIN MUTATIONS IN ACUTE MYELOID LEUKEMIA (2022) (1)
Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q (2021) (1)
Updated definition of cure in adult patients with non-APL acute myeloid leukemia (2015) (1)
Prospective Phase III Trial of Valproic acid (VPA) In Combination with All-Trans Retinoic Acid (ATRA) and Intensive Induction Therapy for AML In Older Patients: The German-Austrian AMLSG 06-04 Study (2010) (1)
Prospective Evaluation of Immunophenotype In Correlation to Genotype In Previously Untreated Adult Patients with Acute Myeloid Leukemia In the Context of the WHO Classification (2010) (1)
Parallel Analyses Disclose Novel Genomic Imbalances in Acute Myeloid Leukemia with Complex Karyotypes. (2005) (1)
MiRNA expression profiling based identification of subclasses in adult acute myeloid leukemia (2007) (1)
MEIS 2 Is an Oncogenic Pa rtner in AML 1-ETO-Positive AML Graphical (1)
Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia (2013) (1)
Genetic and Epigenetic Profiling on 7q22 Identifies ATXN7L1 As Candidate Tumor Suppressor in Acute Myelogenous Leukemia (2011) (1)
Incidence and Prognostic Relevance of ASXL2 Mutations in Adult CBF-AML with t(8;21)(q22;q22): A Study of the German-Austrian AML Study Group (AMLSG) (2015) (1)
The Impact of Therapy-Related and Secondary AML in Relation to Karyotype and Molecular Markers: A Study of the AMLSG. (2007) (1)
Induction Therapy with Idarubicin and Etoposide Combined with Sequential or Concurrent Azacitidine In Patients with High-Risk Acute Myeloid Leukemia: Pilot-Phase of the AMLSG 12-09 Study (2010) (1)
The Methylcytosine Dioxygenase TET3 Is Aberrantly Expressed in Acute Myeloid Leukemia and Promotes AML Growth (2016) (1)
The Mutated Region of Cytoplasmatic Nucleophosmine 1 (NPM1) Elicits Both CD4+ and CD8+ T Cell Responses (2011) (1)
Genetic Heterogeneity of t(8;21)(q22;q22.1) Acute Myeloid Leukemia Revealed By High-Throughput Targeted Sequencing (2017) (1)
Identification of Genomic Imbalances in AML with Complex Karyotype Using Matrix-Based Comparative Genomic Hybridization. (2004) (1)
Prognostic Factors in Adult Patients up to 60 Years with AML and Translocations of Chromosome 11q23: Individual Patient Data Based Analysis of the German AML-Intergroup. (2007) (1)
[Novel therapeutic options in the treatment of BCR/ABL-negative myeloproliferative neoplasms]. (2012) (1)
Assessment of Clonal Evolution in 42 AML with NPM1 Mutations by Molecular Characterization of Paired Diagnosis and Relapse Samples (2011) (1)
Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML) (2019) (1)
Integrative Analysis of NPM1 Mutation-Associated MicroRNA and Gene Expression Signatures Identifies Potential Leukemia-Relevant Genes in Acute Myeloid Leukemia. (2009) (1)
RAS, KIT and FLT3 Gene Mutations in inv(16)/t(16;16)-Positive Acute Myeloid Leukemia (AML): Incidence and Relevance on Clinical Outcome. (2006) (1)
Prognostic Role of Glutathione S-Transferase (GST) Polymorphisms in Acute Myeloid Leukemia. (2007) (1)
Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation (2021) (1)
In Acute Myeloid Leukemia with Complex Karyotype TP53 Alterations Are Associated with Specific Genomic Aberrations and Predict Inferior Survival. (2009) (1)
Acute myeloid leukemia KIT D 816 mutated / CBF-negative acute myeloid leukemia : a poor-risk subtype associated with systemic mastocytosis (2019) (1)
Prognostic Impact of Clonal Hierarchy of Myelodysplasia-Related Gene Mutations in AML Patients (2022) (1)
Combined Analysis of Valproic Acid Induced MicroRNA and Gene Expression Changes in Acute Myeloid Leukemia. (2007) (1)
TP53 Status As Well As Cytogenetic Complexity Significantly Impact on Prognosis in Myelodysplastic Syndromes with Complex (≥3 anomalies) Aberrant Karyotypes (2019) (1)
The Role of PPM1D Mutations in Lenalidomide Resistance and Progression in Patients with MDS and Deletion of Chromosome 5q (2018) (1)
MiR-193a Is a Negative Regulator of Hematopoietic Stem Cells and Promotes Anti-Leukemic Effects in Acute Myeloid Leukemia (2018) (1)
Molecular Characterization of Relapsed Core-Binding Factor (CBF) Acute Myeloid Leukemia (AML) (2015) (1)
Methylation Of The 5’UTR Of Apoptosis Stimulating Protein Of p53-2 (ASPP2) Impairs Gene Expression and Associates With Aggressive Disease and Therapy Failure In Acute Leukemia (2013) (1)
Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs (2015) (1)
mutated / CBF-negative acute myeloid leukemia (2019) (1)
Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms (2013) (1)
Prognosis of Adult Patients ≤60 Years with AML and Aberrations of Chromosome 11q23: Pooled Data Analysis of the German AML-Intergroup. (2006) (1)
Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome—excess blasts detected by next-generation sequencing technique (2021) (0)
GSM454943: Granulocytes UPN43. (2009) (0)
GSE18197: High-resolution SNP-array profiling in myeloproliferative neoplasms. (2009) (0)
A Tumor Suppressor microRNA Defines the Leukemic Hierarchy in Acute Myeloid Leukemia (2015) (0)
Minimal resdiual disease getITD for FLT 3-ITD-based MRD monitoring in AML (2019) (0)
Minimal Residual Disease (MRD) Monitoring in CBFB-MYH11 Acute Myeloid Leukemia (AML) Is of Prognostic Relevance for Relapse-Free Survival. (2006) (0)
GSM454925: Dermal cells UPN23. (2009) (0)
Correction for Jiang et al., Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease (2018) (0)
Fatal outcome in a patient developing Epstein–Barr virus-associated lymphoproliferative disorder (EBV-LPD) without measurable disease (2001) (0)
NF1 Alterations Are Common In AML with Complex Karyotype and Correlate with Specific Genomic Imbalances (2010) (0)
GSM455028: Granulocytes UPN177. (2009) (0)
Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax. (2023) (0)
S106: UBTF-ATXN7L3 GENE FUSION DUE TO 17Q21.31 DELETION DEFINES NOVEL HIGH-RISK ALL SUBTYPE AMENABLE TO MRD-BASED TREATMENT INTENSIFICATION (2022) (0)
Inactivation of the Cell Fate Determinate Llgl1 (Lethal Giant Larvae Homolog 1) Leads to Enhanced HSC Fitness and Predicts a Poor Prognosis in AML. (2012) (0)
GSM455061: Mononuclear cells Nsp7. (2009) (0)
PS968 GENETIC LANDSCAPE OF FLT3-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS TREATED WITHIN THE RATIFY TRIAL: CALGB 10603 (ALLIANCE) (2019) (0)
Aberrant Epigenetic Suppression of the Ptprot Gene Encoding a Protein Tyrosine Phosphatase Targeting KIT in Acute Myeloid Leukemia (2012) (0)
PPM1D Mutations in MDS Patients with Deletion of Chromosome 5q (2017) (0)
GSM455098: Mononuclear cells Sty14. (2009) (0)
GSM455011: Granulocytes UPN130. (2009) (0)
Reduced Intensity Conditioning with Fludarabine, BCNU and Melphalan (FBM) for Allogeneic Hematopoietic Cell Transplantation in Elderly AML Patients: Factors Predicting Outcome (2015) (0)
GSM455050: Granulocytes UPN199. (2009) (0)
Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database (2022) (0)
GSM454918: Granulocytes UPN16. (2009) (0)
GSM455111: Mononuclear cells Sty27. (2009) (0)
GSM454951: Granulocytes UPN52. (2009) (0)
PS1434 GENOMIC LANDSCAPE AND MOLECULAR RISK IN PATIENTS WITH DIPSS LOW- AND INTERMEDIATE-1-RISK PRIMARY MYELOFIBROSIS: A STUDY OF THE GERMAN STUDY GROUP FOR MYELOPROLIFERATIVE NEOPLASMS (GSG-MPN) (2019) (0)
GSM455047: Granulocytes UPN196. (2009) (0)
Impact of Distinct Genetic and Epigenetic Aberrations on Survival and Response in Acute Myeloid Leukemia Patients Receiving Epigenetic Therapy (2016) (0)
Mutational Landscape of Del(9q) Acute Myeloid Leukemia (AML) (2015) (0)
GCLLSG patients treated with alemtuzumab : results from the CLL 2 H trial of the mutations in fludarabine-refractory CLL (2013) (0)
Activity of decitabine combined with all-trans retinoic acid in oligoblastic AML: Results from a randomized 2x2 phase II trial (DECIDER). (2023) (0)
Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1) RUNX1-RUNX1T1 Identifies Patients at High Risk of Relapse: Results of the AML Study Group (AMLSG) (2019) (0)
GSM455069: Mononuclear cells Nsp15. (2009) (0)
KIT Mutations Define Characteristic Gene Expression Signatures in Core Binding Factor Leukemias. (2007) (0)
GSM454916: Granulocytes UPN14. (2009) (0)
Effect of epitopes derived from the mutated region of cytoplasmatic nucleophosmine 1 (NPM1) on CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia. (2012) (0)
Genetic and Epigenetic Silencing of Mesoderm Specific Transcript ( MEST ) In Acute Myelogenous Leukemia. (2010) (0)
Genetic Profiling of BCR/ABL Negative Myeloproliferative Disorders Using High-Resolution Microarrays (2007) (0)
S130: NPM1 MUTATED AML: IMPACT OF CO-MUTATIONAL PATTERNS - RESULTS OF THE EUROPEAN HARMONY ALLIANCE (2022) (0)
The Role of microRNA-155 in Mouse Models of MLL -AML (2015) (0)
Hoxa9/Meis1 Mediate Leukemic Programming through Microrna-155 (2014) (0)
Assessment of the Genomic Landscape of Intermediate Risk Acute Myeloid Leukemia As Defined By 2010 ELN Risk Classification (2018) (0)
Assessment of Treatment Effects By Measurable Residual Disease Monitoring in NPM1-Mutated AML Patients Randomized for Gemtuzumab-Ozogamicin (GO) within the AMLSG 09-09 Trial of the German-Austrian AML Study Group (AMLSG) (2018) (0)
Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia (2021) (0)
The Clinical and Prognostic Influence Of Mutations In The Cohesin Complex In Acute Myeloid Leukemia (2013) (0)
GSM455009: Granulocytes UPN128. (2009) (0)
Impact Of The Pretreatment Characteristics As Well As Cyto- and Molecular-Genetic Profile On Outcome After Relapse In Acute Myeloid Leukemia (2013) (0)
Distinct Biological and Transcriptional Features Of FLT3-ITD Variants In Vitro and In Vivo (2013) (0)
Molecular Characterization Of Myelofibrosis Patients With Cytopenia Treated With Pomalidomide: Results From The Mpnsg 01-09 Study (2013) (0)
GSM455031: Granulocytes UPN180. (2009) (0)
Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study (2021) (0)
Polycythaemia vera (2022) (0)
Gene Expression Analysis of Independent Data Sets Identifies HBG1 to Be Associated with Outcome in Cytogenetically Normal AML. (2009) (0)
Pretreatment Cytogenetic Abnormalities Are Predictive of Induction Success, Cumulative Incidence of Relapse and Overall Survival in Patients >60 Years of Age with Newly Diagnosed Acute Myeloid Leukemia. (2005) (0)
GSM454949: Granulocytes UPN50. (2009) (0)
Experience With IVDR Implementation in Three Diagnostic Laboratories: Messages to EU Health Institutions, Diagnostic Healthcare Payers, and Authorities (2023) (0)
The Biological Influence of Mutation Order on Myeloproliferative Neoplasms * (2015) (0)
GSM454929: Granulocytes UPN28. (2009) (0)
Genome-Wide Genotyping of Acute Myeloid Leukemia with t(9;11) Reveals New Recurrent Genomic Alterations, (2011) (0)
Xenotransplant models in AML: First results of the consortium of the AML BFM Study Group (2009) (0)
GSM454963: Granulocytes UPN64. (2009) (0)
Identification of Distinct inv(16) Subclasses in Adult Acute Myeloid Leukemia Based on Gene Expression Profiling. (2004) (0)
Integrative Genomics Approaches Identify Novel Disease-Related Genetic Aberrations in Acute Myeloid Leukemia (2011) (0)
Abstract LB-073: Epigenome evolution in relapsed acute myeloid leukemia (2016) (0)
In Vivo Methylome Changes in Purified Peripheral Blood Blasts and T Cells of AML Patients Treated with Decitabine: Statistical Modelling of a Hypomethylation Response (2014) (0)
DEK-NUP214 Acute Myeloid Leukemia Depends on CRM1 In Vivo (2022) (0)
GSM455083: Mononuclear cells Nsp29. (2009) (0)
The Human Specific microRNA-941 Is a Key Member of a microRNA Signature of Functionally Validated Leukemic Stem Cells from Patients with Acute Myeloid Leukemia (2016) (0)
Abstract #5608: Synthetic lethal interaction between oncogenic KRAS dependency and suppression of STK33 in human cancer cells (2009) (0)
Symptomatic profiles of 1334 polycythemia vera patients: implications of inadequately controlled disease (2016) (0)
GSM455056: Mononuclear cells Nsp2. (2009) (0)
GSM455084: Mononuclear cells Nsp30. (2009) (0)
Preview : Published ahead of advance online publication Heterodimerization of AML 1 / ETO with CBF b is required for leukemogenesis but not for myeloproliferation (2017) (0)
The retinoic acid receptor co-factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements (2021) (0)
GSM455085: Mononuclear cells Sty1. (2009) (0)
GSM455090: Mononuclear cells Sty6. (2009) (0)
- mutated acute myeloid leukemia NPM 1 Clonal evolution in relapsed (2013) (0)
GSM455079: Mononuclear cells Nsp25. (2009) (0)
GSM454927: Granulocytes UPN26. (2009) (0)
GSM455003: Granulocytes UPN120. (2009) (0)
GSM455053: Granulocytes UPN202. (2009) (0)
Mutational Landscape of Relapsed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) (2020) (0)
GSM454935: Granulocytes UPN35. (2009) (0)
Targeting the WT1mut-Mir-193a Transcriptional Axis with INT-1B3, a Novel Lipid Nanoparticle-Formulated Mir-193a-3p Mimic in Acute Myeloid Leukemia (2022) (0)
Impact of TP53 Mutated Subclones in Acute Myeloid Leukemia (2018) (0)
Circular RNAs of the Nucleophosmin 1 (NPM1) Gene in Acute Myeloid Leukemia Patients (2016) (0)
1030PEvaluation of dose intensification of cytarabine in postremission therapy in older AML patients within the prospective phase II AMLSG 06-04 study (2017) (0)
Acute Myeloid Leukemia with Deletion 9q Is Associated with CEBPA Loss-of-Function Mutations. (2004) (0)
GSM455066: Mononuclear cells Nsp12. (2009) (0)
Andrea factor acute myeloid leukemia Gene expression profiling identifies distinct subclasses of core binding (2007) (0)
GSM455057: Mononuclear cells Nsp3. (2009) (0)
Clinical characterization and prognostic impact of SF 3 B 1 and TP 53 gene mutations in myelodysplastic syndromes (2018) (0)
Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration (2022) (0)
Various Other 3 q Abnormalities in Acute Myeloid Leukemia (2010) (0)
The Non-Canonical, R-Loop Regulatory Function of PIWIL4 Maintains Genomic Integrity and Leukemic Potential of AML Cells (2018) (0)
GSM455082: Mononuclear cells Nsp28. (2009) (0)
GSM454905: Granulocytes UPN3. (2009) (0)
GSM455063: Mononuclear cells Nsp9. (2009) (0)
Familial AML With Germline CEBPA Mutations: Extended Clinical Outcomes and Analysis Of Secondary Mutations Using Whole Exome Sequencing (2013) (0)
GSM454933: Granulocytes UPN33. (2009) (0)
Comorbidities Such As Thromboembolic Events Significantly Worsen Patient-Reported Quality of Life (QoL) and Symptoms in Myeloproliferative Neoplasms (MPN) - Data from the Bioregistry of the German Study Group for MPN (GSG-MPN) (2018) (0)
Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group (2022) (0)
Global and HOX Gene DNA Methylation In Normal Karyotype Acute Myeloid Leukemia: Clinical Implications and Molecular Correlations (2010) (0)
GSM454973: Granulocytes UPN74. (2009) (0)
Prognostic Gene-Expression Signatures in Adult Acute Myeloid Leukemia with Normal Karyotype. (2005) (0)
GSM454958: Granulocytes UPN59. (2009) (0)
GSM455005: Granulocytes UPN122. (2009) (0)
Mutational and immunogenetic landscape of HCV-associated B-cell lymphoproliferative disorders (2021) (0)
GSM454998: Granulocytes UPN110. (2009) (0)
The AML-associated K313 mutation enhances C/EBPα activity by leading to C/EBPα overexpression (2021) (0)
High-Resolution SNP-Array Profiling Discloses Novel Genomic Aberrations in BCR/ABL-Negative Myeloproliferative Neoplasms with Myelofibrosis (2008) (0)
A FLT3 Gene-Expression Signature Outperforms FLT3 Status in Predicting Clinical Outcome for Patients with Normal Karyotype AML. (2006) (0)
Two Long Non-Coding RNAs Are Sufficient to Classify and Significantly Predict In Vivo Engraftment Potential and LSC Properties of Human Acute Myeloid Leukemia Cells (2016) (0)
How a Medical Association Can Make a Difference in a Crisis Situation (2022) (0)
Sequential Molecular Characterization Based Delineation of Potential Driver Aberrations in ACUTE Myeloid Leukemia Following Myelodysplastic Syndrome (2015) (0)
GSM455006: Granulocytes UPN123. (2009) (0)
GSM454908: Granulocytes UPN6. (2009) (0)
GSM455049: Granulocytes UPN198. (2009) (0)
Outcome of Older AML Patients with Adverse Cytogenetics, Including Single or Multiple Monosomies, Treated with the DNA Hypomethylating Agent Decitabine (2011) (0)
Aberrantly expressed TET1 in T-ALL regulates DNA repair and leukemic growth via maintenance of 5-hydroxymethylome and can be antagonized by the parp inhibitor Olaparib (2017) (0)
GSM455036: Granulocytes UPN185. (2009) (0)
Array-CGH and Gene Expression Profiling Based Molecular Characterization of Myeloid Leukemia Cell Lines. (2005) (0)
GSM454904: Granulocytes UPN2. (2009) (0)
Isocitrate Dehydrogenase Gene Mutations In Elderly Patients with Acute Myeloid Leukemia (AML) and Outcome After Treatment with All-Trans Retinoic Acid: A Study of the German-Austrian AML Study Group (AMSLG) (2010) (0)
Unmet Needs for Symptom Control in Essential Thrombocythemia with Front Line Therapy (2015) (0)
Impact of Pegfilgrastim and Dosing Schedule of Cytarabine on Hematological Reconstitution Times, Incidences of Severe Infection and Duration of Hospitalization after Consolidation Therapy with High-Dose Cytarabine in Acute Myeloid Leukaemia - Interim Results from AMLSG 07-04 Trial. (2007) (0)
Identification of High-Level DNA Amplifications in AML with Complex Karyotype Using Array-CGH. (2006) (0)
GSM455021: Granulocytes UPN170. (2009) (0)
Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN) (2023) (0)
GSM455104: Mononuclear cells Sty20. (2009) (0)
GSM455071: Mononuclear cells Nsp17. (2009) (0)
Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET (2023) (0)
GSM454947: Granulocytes UPN48. (2009) (0)
Measuring Disease Burden in Myeloid Malignancies/Residual Disease (2020) (0)
Clinicohematologic and Molecular Response of Essential Thrombocythemia Patients Treated with Pegylated Interferon-Alpha: A Multicenter Study on Behalf of the German Study Group-MPN (GSG-MPN) (2022) (0)
GSM454967: Granulocytes UPN68. (2009) (0)
GSM454959: Granulocytes UPN60. (2009) (0)
Prospective Phase III Trial Of Valproic Acid (VPA) In Combination With All-Trans Retinoic Acid (ATRA) and Intensive Induction Therapy For AML In Older Patients: Final and Molecular Subset Analyses Of The AMLSG 06-04 Study (2013) (0)
Wnt and Notch Pathways Regulate Stemness of Myeloid Leukemia Cells Via IL33/ST2 Signaling (2022) (0)
P456: A LONG READ SEQUENCING AND CRISPR-CAS9 BASED APPROACH FOR RAPID COPY-NUMBER ALTERATION AND STRUCTURAL VARIATION DETECTION IN HEMATOLOGIC MALIGNANCIES (2022) (0)
GSM455087: Mononuclear cells Sty3. (2009) (0)
GSM454971: Granulocytes UPN72. (2009) (0)
GSM455041: Granulocytes UPN190. (2009) (0)
GSM454903: Granulocytes UPN1. (2009) (0)
GSM454997: Granulocytes UPN109. (2009) (0)
ABCB1 Expression in Acute Myeloid Leukemia (AML): A Possible Predictive Value for Treatment Resistance? (2014) (0)
GSM454969: Granulocytes UPN70. (2009) (0)
GSM454931: Granulocytes UPN30. (2009) (0)
TET1 Promotes Leukemic Growth in T-ALL Via Maintenance of 5-Hydroxymethylation Marks and Can be Antagonized By the PARP Inhibitor Olaparib (2016) (0)
GSM455077: Mononuclear cells Nsp23. (2009) (0)
Treatment Results In Acute Myeloid Leukemia Over a Time Period Of 20 Years: Analysis Of The German-Austrian Acute Myeloid Leukemia Study Group (AMLSG) (2013) (0)
Disclosure of Copy Number Alterations in AML with Normal Karyotype Using Matrix-Based Comparative Genomic Hybridization. (2005) (0)
GSM454995: Granulocytes UPN107. (2009) (0)
Aberrantly expressed stem cell associated protein PIWIL4 acts as a piRNA binding, epigenetically active and growth regulatory factor in human acute myeloid leukemia (2017) (0)
GSM455025: Granulocytes UPN174. (2009) (0)
Is Longer MDS Duration Prior to Non-Intensive AML Treatment a Favorable Prognostic Factor? Results of the 00331 Multicenter Phase II Decitabine Trial (2010) (0)
Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database (2021) (0)
Poster: AML-440 Prognosis of Molecularly-Defined Secondary Acute Myeloid Leukemia Patients (2022) (0)
Personally tailored cancer management based on knowledge banks of genomic and clinical data (2016) (0)
GSM454936: Granulocytes UPN36. (2009) (0)
GSM454939: Granulocytes UPN39. (2009) (0)
GSM454993: Granulocytes UPN105. (2009) (0)
Distinct Expression Patterns in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Characterized by Uniparental Disomy. (2008) (0)
GSM454955: Granulocytes UPN56. (2009) (0)
KIT D816 Mutated / CBF-Negative Acute Myeloid Leukemia (AML): A New Poor-Risk Subtype Associated with Systemic Mastocytosis (SM-AML) (2018) (0)
GSM454957: Granulocytes UPN58. (2009) (0)
The miRNA-193B is a potent tumor-suppressor and a biomarker for poor prognosis in acute myeloid leukemia (2017) (0)
GSM455017: Granulocytes UPN136. (2009) (0)
GSM454972: Granulocytes UPN73. (2009) (0)
AML-440 Prognosis of Molecularly-Defined Secondary Acute Myeloid Leukemia Patients. (2022) (0)
GSM455035: Granulocytes UPN184. (2009) (0)
Expression of Tumor-Associated Antigens (TAAs) in Acute Myeloid Leukemia (AML) Correlated with Specific T Cell Responses and Survival. (2006) (0)
Mutated Nucleophosmin 1 (NPM1) Is an Immunogenic Target and Patients with NPM1 mut Acute Myeloid Leukemia (AML) Showed High Expression of Different Leukemia-Associated Antigens (LAAs) (2012) (0)
GSM454976: Granulocytes UPN77. (2009) (0)
mutations as cooperative genetic lesions in t(8;21)-positive acute myeloid leukemia (2006) (0)
Stratification of Postremission Therapy in Patients with Acute Myeloid Leukemia < 60 Years According to the Karyotype: Results of the German Multicenter Treatment Trials AML HD93 and AML HD98-A (2001) (0)
GSM455106: Mononuclear cells Sty22. (2009) (0)
Impact of Different Postremission Strategies in Younger Adults with Acute Myeloid Leukemia and Normal Karyotype Exhibiting a CEBPA Mutation. (2005) (0)
GSM454981: Granulocytes UPN82. (2009) (0)
GSM454910: Granulocytes UPN8. (2009) (0)
GSM455078: Mononuclear cells Nsp24. (2009) (0)
GSM454991: Granulocytes UPN103. (2009) (0)
The Nucleophosmin-1 Splice Variant Analysis Provides More Important Information On Prognosis Than NPM1 Mutational Status In Acute Myeloid Leukemia (2013) (0)
Treatment of a Patient with Refractory Non-Langerhans-Cell-Histiocytosis with the Tyrosine Kinase Inhibitor Sorafenib: Clinical and Genetic Implications (2010) (0)
Impact of Donor Type on Outcome after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients: Analysis of the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG) (2014) (0)
Phase I/II Study on Cytarabine and Idarubicin Combined with Escalating Doses of Clofarabine in Untreated Patients with Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSG 17-10 CIARA) (2016) (0)
Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial (2023) (0)
GSM455051: Granulocytes UPN200. (2009) (0)
GSM455043: Granulocytes UPN192. (2009) (0)
GSM455107: Mononuclear cells Sty23. (2009) (0)
GSM455094: Mononuclear cells Sty10. (2009) (0)
GSM455027: Granulocytes UPN176. (2009) (0)
Clinical Impact of TET2 Mutations in Acute Myeloid Leukemia Patients Harboring CEBPA Mutations: A Study of the AML Study Group (AMLSG) (2013) (0)
GSM455081: Mononuclear cells Nsp27. (2009) (0)
Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN) (2022) (0)
The Renovated Face of EHA Classical Master Class: A Survey-based Evaluation on Behalf of the EHA Campus Working Group (2022) (0)
Supplementary information Inactivating CUX1 mutations promote tumorigenesis (2013) (0)
SNP-Array Profiling Identifies Complex Aberrations and Candidate Genes in Myeloproliferative Neoplasms with Leukemic Transformation. (2009) (0)
In Vitro and In Vivo Monitoring of Valproic Acid Effects on Gene Expression Signatures in Adult Acute Myeloid Leukemia. (2006) (0)
NGS-Based Monitoring of Measurable Residual Disease in FLT3-ITD Positive Acute Myeloid Leukemia (2018) (0)
ATRA resistance in AML patients MN1 overexpression induces acute myeloid leukemia in mice and predicts (2013) (0)
Changes of the Mutational Landscape in Relapsed Acute Myeloid Leukemia (2016) (0)
A Lack of Diversity, Equity, and Inclusion in Clinical Research Has Direct Impact on Patient Care (2023) (0)
GSM455114: Mononuclear cells Sty30. (2009) (0)
GSM455033: Granulocytes UPN182. (2009) (0)
Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation (2019) (0)
GSM455092: Mononuclear cells Sty8. (2009) (0)
GSM454917: Granulocytes UPN15. (2009) (0)
MLL/AF9 Fusion Transcript Quantification in t(9;11)-Positive AML Identify Patients with High Risk of Relapse. (2004) (0)
GSM454961: Granulocytes UPN62. (2009) (0)
GSM455073: Mononuclear cells Nsp19. (2009) (0)
GSM455058: Mononuclear cells Nsp4. (2009) (0)
GSM454944: Granulocytes UPN44. (2009) (0)
The Mir-193 Family Antagonizes Stem Cell Pathways and Is a Potent Tumor Suppressor in Childhood and Adult Acute Myeloid Leukemia (2015) (0)
GSM454912: Granulocytes UPN10. (2009) (0)
Publisher Correction: Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN (2021) (0)
GSM454919: Granulocytes UPN18. (2009) (0)
NPM1 Splice Variant R2 Reveals Biological and Clinical Consequences of Prognostic Value in Acute Myeloid Leukemia (2014) (0)
The Homeobox Gene VENTX Collaborates with AML1-ETO in Inducing an Acute Leukemia in Mice (2015) (0)
The Lef1 isoform, lacking the β-catenin binding domain, is not acting as a dominant negative Lef1 variant, but is a hematopoietic active protein with unique DNA binding properties (2016) (0)
Rapid and Reproducible Karyotyping with Nanopore Sequencing in AML Patients (2022) (0)
Activation of a Mir-181-Targeting HOXA-PBX3 Homeobox Gene Signature Is Associated with Adverse Prognosis of Cytogenetically Abnormal Acute Myeloid Leukemia (2011) (0)
Acute Myeloid Leukemia (AML): Prospective Comparison of Different Treatments with a Common Standard Treatment - A Study by the German AML Intergroup (2010) (0)
GSM455023: Granulocytes UPN172. (2009) (0)
Abstract 1307: Heritable polymorphism predisposes to high expression ofBAALCin cytogenetically normal acute myeloid leukemia (CN-AML) (2012) (0)
In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts. (2023) (0)
GSM455102: Mononuclear cells Sty18. (2009) (0)
Impact of Gene Expression Profiling on Diagnosis and Prognostication in Cytogenetically Normal AML. (2008) (0)
GSM455001: Granulocytes UPN118. (2009) (0)
GSM455095: Mononuclear cells Sty11. (2009) (0)
BRCA1/2 Containing Complex 3 (BRCC36) Is Recurrently Mutated in AML with t(8;21) and Associated with Increased Sensitivity to Chemotherapy through Impairment of the DNA Damage Repair Pathway (2018) (0)
Invited lecture: Array-CGH and correlation with gene expression profile in adult AML with complex karyotype (2006) (0)
GSM454921: Granulocytes UPN20. (2009) (0)
GSM454941: Granulocytes UPN41. (2009) (0)
The Adhesion Molecule “G-Protein Coupled Receptor 56” (Gpr56) Cooperates with the Homeobox Gene Hoxa9 to Induce Acute Myeloid Leukemia in Mice (2014) (0)
The dioxygenase TET3 is aberrantly high expressed in acute myeloid leukemia, promotes leukemic growth and impairs myeloid differentiation of normal hematopoietic stem progenitors (2017) (0)
Genomic Landscape and Molecular Risk in Patients with Advanced Myelofibrosis Treated within the Multicenter Phase Ib/II MPNSG0212 (POMINC) Trial (2021) (0)
GSM454978: Granulocytes UPN79. (2009) (0)
Tet1 promotes leukemic growth of AML1-ETO+ AML via 5-hydroxymethylcytosine marks and its oncogenic role and high expression can be antagonized using Olaparib, an inhibitor of its binding partner PARP1 (2017) (0)
GSM455039: Granulocytes UPN188. (2009) (0)
Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for NPM1m Patients Achieving MRD-Negative CR after Intensive Induction (2022) (0)
GSM455109: Mononuclear cells Sty25. (2009) (0)
P1055: CLINICAL AND GENETIC RESULTS OF THE PHASE IB/II TRIAL MPNSG-0212: RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA (2022) (0)
GSM454988: Granulocytes UPN89. (2009) (0)
GSM455020: Granulocytes UPN169. (2009) (0)
GSM454987: Granulocytes UPN88. (2009) (0)
PF260 PROGNOSTIC AND PREDICTIVE IMPACT OF NPM1/FLT3-ITD GENOTYPES AS DEFINED BY 2017 EUROPEAN LEUKEMIANET RISK CATEGORIZATION FROM AML PATIENTS TREATED WITHIN THE INTERNATIONAL RATIFY STUDY (2019) (0)
GSM455013: Granulocytes UPN132. (2009) (0)
GSM455019: Granulocytes UPN162. (2009) (0)
GSM454928: Granulocytes UPN27. (2009) (0)
Prognostic Impact of BAALC Expression in the Context of Other Molecular Markers in Cytogenetically Normal Acute Myeloid Leukemia. (2007) (0)
GSM455096: Mononuclear cells Sty12. (2009) (0)
GSM454990: Granulocytes UPN102. (2009) (0)
P532: ACUTE MYELOID LEUKEMIA (AML): UNICENTRIC REPORT ON 1029 PATIENTS DIAGNOSED IN TERTIAL REFERAL CENTER (2022) (0)
The HOXA/PBX3 Pathway Is an Attractive Therapeutic Target in MLL-Rearranged Acute Leukemia (2012) (0)
P394: INSIGHTS INTO PATIENT-DERIVED XENOGRAFT MODELS FOR DEK-NUP214 LEUKEMIA (2022) (0)
Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia (2022) (0)
Characteristics and Prognosis of AML Patients with or without a History of Clonal Hematopoiesis (2015) (0)
An Adapted Gating Strategy Integrating a Myelomonocytic Window Is Necessary For Correct Flow Cytometric Diagnosis In a Large Proportion Of AML With Mutated NPM1 (2013) (0)
Survival Prediction Acute Myeloid Leukemia (AML) Using a Combination of DNA Methylation Analysis and Gene Expression Profiling. (2005) (0)
PF256 RATIFY: PROGNOSTIC IMPACT OF FLT3 TYROSINE KINASE DOMAIN (TKD) AND NPM1 MUTATION STATUS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) TREATED WITH MIDOSTAURIN + STANDARD CHEMOTHERAPY (2019) (0)
GSM455065: Mononuclear cells Nsp11. (2009) (0)
Minimal Residual Disease (MRD) Monitoring in NPM1 Mutated Acute Myeloid Leukemia (AML): Impact of Concurrent FLT3-ITD and DNMT3A Mutations on MRD Kinetics and Clinical Outcome (2013) (0)
Loss of Phospholipase C Gamma 1 (PLCG1) Impairs AML1-ETO Induced Leukemia Stem Cell Self-Renewal (2019) (0)
Defects in the RAS/RTK Signaling Pathways Predominate the Mutational Spectrum of EVI1/GATA2 Rearranged Myeloid Malignancies with Inv(3)/t(3;3) (2014) (0)
Activity of Decitabine (DAC) Combined with All-Trans Retinoic Acid (ATRA) in Oligoblastic AML: Subgroup Analysis of a Randomized 2x2 Phase II Trial (2020) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Konstanze Döhner?

Konstanze Döhner is affiliated with the following schools:

University of Ulm
Hannover Medical School
University of Tübingen
Technical University of Munich
University of Münster

Konstanze Döhner's Academic­Influence.com Rankings

Why Is Konstanze Döhner Influential?

Konstanze Döhner's Published Works

Published Works

What Schools Are Affiliated With Konstanze Döhner?

Konstanze Döhner's AcademicInfluence.com Rankings